3B Blackbio DX Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 14 Jun 2026 | Healthcare Services | Market Cap: ₹1.0K Cr
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
From 3B Blackbio DX Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,202
Market Cap
₹1.0K Cr
P/E Ratio
17.7
Revenue Rank
Margin Rank
How does 3B Blackbio DX Ltd rank in Healthcare Services?
Compare 3B Blackbio DX Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →The company targets a revenue growth of 15% to 20% for FY27 and onward.
- →Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28.
- →The overall consolidated topline for FY27 is expected to be INR175-180 crores.
- →The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%.
- →Competition from China affects a small product segment but is not expected to impact the core high-margin AMR panel business.
- →Market growth is anticipated at 8%-10% over the next 2-3 years, with the company maintaining approximately 15% market share.
- →Growth is supported by new product launches such as sample-to-answer systems expected around Q3-Q4, and ongoing US FDA approvals enhancing global presence.
📈 Profitability & Margins
No information- →3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
- →EBITDA margins are projected to maintain or slightly improve, with consolidated EBITDA margins expected around 40%-45% excluding other income.
- →Coris segment is anticipated to become slightly EBITDA positive in FY27, aiming for 5% to 10% EBITDA margin by FY28.
- →Overall EBITDA growth is expected to mirror revenue growth (15%-20%), with Coris EBITDA flat or marginally positive in the near term.
- →Depreciation for FY27 is estimated around INR 4.5 to 5 crores annually.
- →The company plans strong margin profiles supported by high-margin segments like AMR; competitive pressure from China is limited to a small product segment.
- →EPS growth is implied aligned with revenue and EBITDA growth targets, though specific EPS figures were not disclosed.
🏗️ Capital Expenditure Plans
Yes- →The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
- →Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores.
- →Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments.
- →There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities.
- →M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates.
- →The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals.
- →Slight uncertainties exist on timing; M&A closures are expected during the year but exact Q1/Q2 timing is not guaranteed.
- →Treasury investments are diversified into equity mutual funds (5-7%), fixed deposits (30-35%), treasury bonds (30-35%), and AAA-rated corporate bonds, maintaining liquidity for acquisitions.
💰 Fundraising & Capital Structure
No- →There is no explicit mention of any current or planned fundraising through debt or equity.
- →The company is holding significant cash and investments (~INR230 crores) and plans to use this for M&A opportunities.
- →Management mentions a preference to keep reserves (~INR50 crores) to be ready for acquisitions rather than raising fresh capital.
- →Expansion needs minimal capital (INR4-5 crores), supported by strong free cash flow (~INR40 crores annually).
- →No concrete timeline for raising funds; focus is on utilizing existing treasury assets and internal accruals.
- →M&A discussions are ongoing with hopes to close deals within the year but depend on valuation and due diligence, not fundraising.
- →Overall, emphasis is on organic growth and acquisitions funded by internal cash rather than fresh equity or debt.
📋 Order Book & Pipeline
No information- →Coris contract initially was Euro 6 million for four years starting 2024.
- →Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million).
- →Around Euro 2.4 million remains to be executed through FY28.
- →The Coris HAT order is expected to remain broadly similar in the current year.
- →Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays.
- →For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive.
- →Market demand projected to grow at 8% to 10%, with 3B BlackBio maintaining around 15% market share.
- →No major market glut expected from China or competitors in India or export markets due to regulatory barriers.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
- Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
- Vimta Labs (Q4 FY26)
. Key concall takeaways from Vimta Labs Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q4 FY26 results?
The company targets a revenue growth of 15% to 20% for FY27 and onward. 3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a below-average growth signal. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.